Please ensure Javascript is enabled for purposes of website accessibility

Growing Aches and Pains Sink Rigel Pharmaceuticals

By Sean Williams - Apr 5, 2013 at 1:11PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Mixed late-stage trial data backs Rigel's rheumatoid arthritis drug up against the wall.

Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.

What: Shares of Rigel Pharmaceuticals (RIGL 5.00%) imploded today, losing as much as 37% of its value after licensing partner AstraZeneca (AZN 1.05%) announced that the first phase 3 study of Fostamatinib failed to meet one of the two designed primary endpoints of the trial.

So what: Fostamatinib -- a treatment for rheumatoid arthritis, or RA, which is a progressive disease that causes inflammation of the joints and surrounding tissues – achieved a statistically significant improvement in the ACR20 response rate in terms of symptoms for both dosage subsets at 24 weeks. However, it didn't show any improvement with regard to progression of joint damage according to x-ray tests. Further, Fostamatinib was generally well-tolerated in trials, but it once again did lead to hypertension, which is a concern not taken lightly by the Food and Drug Administration.

Now what: That's now two strikes for Rigel Pharmaceuticals with Fostamatinib -- one more and it and the drug can take a seat on the bench as far as I'm concerned. In December, Fostamatinib proved to be an inferior treatment option for patients with RA in a direct comparison to AbbVie's (ABBV -0.38%) blockbuster drug Humira -- strike one. Today, it failed to demonstrate any statistically significant improvement in suppressing joint damage -- strike two. Tack on the fact that Pfizer's (PFE -0.15%) Xeljanz, another FDA-approved treatment for RA, scored higher than Fostamatinib in its ACR20 response rate in its phase 3 tests and doesn't have hypertension concerns, and you can see that even if Fostamatinib somehow gains approval, its uses appear to be extremely limited. Rigel still has two additional late-stage trials ongoing with Fostamatinib, but the expectation that they will be a success are quickly waning.

Craving more input? Start by adding Rigel Pharmaceuticals to your free and personalized watchlist so you can keep up on the latest news with the company.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

AstraZeneca PLC Stock Quote
AstraZeneca PLC
AZN
$67.40 (1.05%) $0.70
Rigel Pharmaceuticals, Inc. Stock Quote
Rigel Pharmaceuticals, Inc.
RIGL
$1.89 (5.00%) $0.09
Pfizer Inc. Stock Quote
Pfizer Inc.
PFE
$53.91 (-0.15%) $0.08
AbbVie Inc. Stock Quote
AbbVie Inc.
ABBV
$150.00 (-0.38%) $0.57

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
356%
 
S&P 500 Returns
124%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/28/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.